Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Frequently Asked Questions / Types of Cancer / Brain Tumors / Brain Tumors
Last Modified: September 16, 2007
![]()
Dear OncoLink "Ask The Experts,"
Our 16-year-old son died after being diagnosed with an astrocytoma; however, the autopsy confirmed GBM, or Glioblastoma multiforme. His only symptoms were headaches. Do GBM tumors start out as astrocytomas and then progress to GBM? How long would it take an astrocytoma to form into a GBM?
![]()
Christopher Dolinsky, MD, Assistant Chief Resident in the Department of Radiation Oncology at the Hospital of the University of Pennsylvania, responds:
Glioblastoma multiforme (GBM) represents the most aggressive form of astrocytomas, which are a spectrum of tumors arising from cells called astrocytes. Hence, GBM is actually just one subtype of astrocytoma, also known as a Grade 4 astrocytoma. Incidentally, astrocytes are actually one of many types of "glial cells", or supporting cells of the central nervous system. All cancers involving glial cells are thus collectively known as "gliomas". Put another way, GBM's are listed under the larger general category of astrocytomas, which in turn are listed under the larger heading of gliomas.
GBM's are the most common type of primary brain tumor; metastases to brain from other primary tumor sites remain the most common type of brain cancer overall. As mentioned above, GBM's are considered Grade 4 astrocytomas by the World Health Organization (WHO) grading system. GBMs can actually develop from lower grade gliomas, like grade 2 or grade 3 astrocytomas. GBMs can also form directly from normal brain cells (astrocytes) without going through lower grades. The particular pattern of genetic mutations in the cells ultimately dictates which grade of tumor will develop. It is more common for GBMs to develop from lower grade tumors in younger patients; however, it is not the kind of thing that happens over a short time. If there is a change in the diagnosis within a short time, it is more likely that the first diagnosis was incorrect. This is often the case because initial biopsies, in the interest of safety, may be relatively small in size and thus contain small amounts of tumor to examine under a microscope. The pathologist who makes the diagnosis may not see all of the features present in order to classify something as a GBM. However, at autopsy, the entire specimen can be examined and then a more accurate diagnosis can be obtained.
Marianna provides tips for people starting cancer treatments and talks about the cancer experience. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

